-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Private Equity Firms Among Everest Medicines Limited's (HKG:1952) Largest Stockholders and Were Hit After Last Week's 12% Price Drop
Private Equity Firms Among Everest Medicines Limited's (HKG:1952) Largest Stockholders and Were Hit After Last Week's 12% Price Drop
If you want to know who really controls Everest Medicines Limited (HKG:1952), then you'll have to look at the makeup of its share registry. And the group that holds the biggest piece of the pie are private equity firms with 52% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company.
As a result, private equity firms as a group endured the highest losses last week after market cap fell by HK$429m.
Let's take a closer look to see what the different types of shareholders can tell us about Everest Medicines.
View our latest analysis for Everest Medicines
SEHK:1952 Ownership Breakdown September 7th 2022What Does The Institutional Ownership Tell Us About Everest Medicines?
Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.
As you can see, institutional investors have a fair amount of stake in Everest Medicines. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Everest Medicines' historic earnings and revenue below, but keep in mind there's always more to the story.
SEHK:1952 Earnings and Revenue Growth September 7th 2022Our data indicates that hedge funds own 5.8% of Everest Medicines. That worth noting, since hedge funds are often quite active investors, who may try to influence management. Many want to see value creation (and a higher share price) in the short term or medium term. CBC Group is currently the largest shareholder, with 43% of shares outstanding. For context, the second largest shareholder holds about 8.9% of the shares outstanding, followed by an ownership of 5.8% by the third-largest shareholder.
To make our study more interesting, we found that the top 2 shareholders have a majority ownership in the company, meaning that they are powerful enough to influence the decisions of the company.
While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. Quite a few analysts cover the stock, so you could look into forecast growth quite easily.
Insider Ownership Of Everest Medicines
While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.
Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.
Our most recent data indicates that insiders own some shares in Everest Medicines Limited. In their own names, insiders own HK$49m worth of stock in the HK$3.1b company. Some would say this shows alignment of interests between shareholders and the board. But it might be worth checking if those insiders have been selling.
General Public Ownership
The general public-- including retail investors -- own 29% stake in the company, and hence can't easily be ignored. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.
Private Equity Ownership
With an ownership of 52%, private equity firms are in a position to play a role in shaping corporate strategy with a focus on value creation. Sometimes we see private equity stick around for the long term, but generally speaking they have a shorter investment horizon and -- as the name suggests -- don't invest in public companies much. After some time they may look to sell and redeploy capital elsewhere.
Next Steps:
I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. For example, we've discovered 3 warning signs for Everest Medicines (1 is concerning!) that you should be aware of before investing here.
But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
如果你想知道誰真正控制了珠穆朗瑪峰醫藥有限公司(HKG:1952),那麼你就得看看它的股票登記簿的構成。而在這塊蛋糕上分得最大一塊蛋糕的是擁有52%股權的私募股權公司。換句話說,該集團將從他們對公司的投資中獲得最大(或損失最大)。
其結果是,在市值縮水4.29億港元后,私人股本公司作為一個整體上週遭受了最大的損失。
讓我們仔細看看不同類型的股東能告訴我們關於珠穆朗瑪峰醫藥公司的什麼。
查看我們對珠穆朗瑪峰藥品的最新分析
聯交所:1952年9月7日所有權分類關於珠穆朗瑪峰醫藥,機構所有權告訴了我們什麼?
機構通常在向自己的投資者報告時,以基準來衡量自己,因此一旦一隻股票被納入主要指數,它們往往會對這只股票變得更加熱情。我們預計,大多數公司都會有一些機構登記在冊,特別是在它們正在增長的情況下。
正如你所看到的,機構投資者在珠穆朗瑪峰醫藥公司擁有相當數量的股份。這意味著為這些機構工作的分析師已經看過了這只股票,他們喜歡它。但就像其他人一樣,他們也可能錯了。當多家機構持有一隻股票時,它們總是面臨“擁擠交易”的風險。當這樣的交易出錯時,多方可能會競相快速拋售股票。在一家沒有增長曆史的公司,這一風險更高。你可以在下面看到珠穆朗瑪峰醫藥公司的歷史收益和收入,但請記住,故事中總是有更多的東西。
聯交所:1952年盈利及收入增長2022年9月7日我們的數據顯示,對沖基金擁有珠穆朗瑪峰醫藥公司5.8%的股份。這一點值得注意,因為對沖基金往往是相當活躍的投資者,他們可能會試圖影響管理層。許多人希望在短期或中期看到價值創造(以及更高的股價)。CBC集團目前是最大股東,持有43%的流通股。作為參考,第二大股東持有約8.9%的流通股,第三大股東持有5.8%的股份。
為了讓我們的研究更有趣,我們發現,前兩名股東擁有公司的多數股權,這意味著他們足夠強大,可以影響公司的決策。
雖然研究一家公司的機構所有權數據是有意義的,但研究分析師的情緒以瞭解風向也是有意義的。相當多的分析師追蹤這只股票,所以你可以很容易地研究預測增長。
珠穆朗瑪峰醫藥的內部人所有權
儘管對內部人的準確定義可能是主觀的,但幾乎每個人都認為董事會成員是內部人。公司管理層管理企業,但首席執行官將向董事會負責,即使他或她是董事會成員。
大多數人認為內部人持股是積極的,因為它可以表明董事會與其他股東很好地結盟。然而,在某些情況下,太多的權力集中在這個群體中。
我們的最新數據顯示,內部人士持有珠穆朗瑪峰醫藥有限公司的部分股份。內部人士以個人名義持有這家市值31億港元的公司價值4900萬港元的股票。有人會說,這表明股東和董事會之間的利益一致。但或許值得一查的是,這些內部人士是否一直在拋售。
一般公有制
包括散戶投資者在內的普通公眾持有該公司29%的股份,因此不能輕易忽視。儘管這種規模的所有權可能不足以影響有利於他們的政策決定,但他們仍然可以對公司政策產生集體影響。
私募股權所有權
私募股權公司擁有52%的股權,能夠在塑造專注於價值創造的公司戰略方面發揮作用。有時我們會看到私募股權投資長期存在,但總的來說,它們的投資期限較短,而且--顧名思義--不會對上市公司進行太多投資。一段時間後,他們可能會考慮出售並將資本重新配置到其他地方。
接下來的步驟:
我發現看看到底是誰擁有一家公司是非常有趣的。但為了真正獲得洞察力,我們還需要考慮其他資訊。例如,我們發現珠穆朗瑪峰醫藥的3個警告標誌(1是關於!)在這裡投資之前你應該意識到這一點。
但最終這就是未來,而不是過去,這將決定這家企業的所有者將做得多好。因此,我們認為,看看這份免費報告是明智的,它顯示了分析師是否預測到了更光明的未來。
注:本文中的數位是使用過去12個月的數據計算的,指的是截至財務報表日期的最後一個月的12個月期間。這可能與全年的年度報告數位不一致。
對這篇文章有什麼反饋嗎?擔心內容嗎?保持聯繫直接與我們聯繫。或者,也可以給編輯組發電子郵件,地址是implywallst.com。
本文由Simply Wall St.撰寫,具有概括性。我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議。它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況。我們的目標是為您帶來由基本面數據驅動的長期重點分析。請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內。Simply Wall St.對上述任何一隻股票都沒有持倉。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧